Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Total Liabilities (2016 - 2025)

Ligand Pharmaceuticals' Total Liabilities history spans 16 years, with the latest figure at -$1.0 billion for Q4 2025.

  • For Q4 2025, Total Liabilities fell 1013.65% year-over-year to -$1.0 billion; the TTM value through Dec 2025 reached -$1.0 billion, down 1013.65%, while the annual FY2025 figure was -$1.0 billion, 1013.65% down from the prior year.
  • Total Liabilities for Q4 2025 was -$1.0 billion at Ligand Pharmaceuticals, down from $526.6 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $549.3 million in Q1 2021 and bottomed at -$1.0 billion in Q4 2025.
  • The 5-year median for Total Liabilities is $143.0 million (2023), against an average of $177.6 million.
  • The largest YoY upside for Total Liabilities was 363.2% in 2025 against a maximum downside of 1013.65% in 2025.
  • A 5-year view of Total Liabilities shows it stood at $476.4 million in 2021, then plummeted by 65.33% to $165.2 million in 2022, then crashed by 47.75% to $86.3 million in 2023, then rose by 29.0% to $111.3 million in 2024, then tumbled by 1013.65% to -$1.0 billion in 2025.
  • Per Business Quant, the three most recent readings for LGND's Total Liabilities are -$1.0 billion (Q4 2025), $526.6 million (Q3 2025), and $121.3 million (Q2 2025).